葵花药业：自筹不超5000万元开展产品研发立项工作

Core Viewpoint - The company has approved a funding of up to 50 million yuan for various drug development projects, indicating a strategic focus on expanding its product offerings and enhancing its research capabilities [1] Group 1: Product Development Initiatives - The company will initiate research and development for traditional Chinese medicine with the same name and formula [1] - The company plans to develop generic drugs that are equivalent to the consistency evaluation projects [1] - There will be efforts to expand existing products by adding new indications [1] Group 2: Management and Oversight - The management team has been authorized to oversee the progress and specific matters related to the R&D projects [1] - The decision falls within the board's authority and does not require shareholder approval [1]